Multiple Myeloma

Bispecifics in the Treatment of Multiple Myeloma: Teclistamab

Sikander Ailawadhi, MD, discussed the safety and efficacy of talquetamab in heavily pretreated patients with relapsed/refractory multiple myeloma following a readout of the phase 1/2 MonumenTAL-1 trial.

Melissa Alsina, MD;Rachid Baz, MD;Brandon Blue, MD;Ken Shain, MD, PhD

Sequencing Therapies in Relapsed/Refractory Multiple Myeloma

Panelists review data from the MajesTEC-1 clinical trial and elucidate the role of teclistamab therapy in patients with relapsed/refractory multiple myeloma.

Melissa Alsina, MD;Rachid Baz, MD;Brandon Blue, MD;Ken Shain, MD, PhD

FDA Grants Fast Track and RMAT Designations to CAR T Product for R/R Myeloma

Shared insight on the value of using effective regimens upfront and optimal sequencing throughout several lines of therapy in multiple myeloma.

$The investigational CAR T-cell therapy equecabtagene autoleucel receives fast track and regenerative medicine advanced therapy designations for managing relapsed or refractory multiple myeloma.$

Russ Conroy

Step-Up Doses in Patients Receiving Teclistamab for Multiple Myeloma

The investigational CAR T-cell therapy equecabtagene autoleucel receives fast track and regenerative medicine advanced therapy designations for managing relapsed or refractory multiple myeloma.

Process of Administering Teclistamab and Other Bispecific Agents

A review of the process of “step-up” doses in teclistamab therapy for multiple myeloma and their use.

Updated Data from KarMMA-3 Show Improved PFS in Relapsed/Refractory Myeloma

A review of the process of giving a patient a dose of teclistamab from start to finish.

$Survival appears to be significantly improved when idecabtagene vicleucel is given vs standard of care in relapsed/refractory multiple myeloma.$

Ariana Pelosci

February 14th 2023

Survival appears to be significantly improved when idecabtagene vicleucel is given vs standard of care in relapsed/refractory multiple myeloma.

Review of Patient Subgroups in Transplant-Ineligible NDMM

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD

Clinical Trials in Transplant-Ineligible NDMM

Oncology expert panelists review patient subgroup analyses for MAIA and SWOG0777 studies, investigating treatments for transplant-ineligible patients with newly diagnosed multiple myeloma.

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD

Non–BCMA-Targeting Bispecific Antibodies in R/R MM

Expert panelists review clinical data from studies investigating treatment regimens for patients with NDMM that are transplant-ineligible.

Sagar Lonial, MD, FACP;Sandy Wong, MD;Caitlin Costello, MD;Timothy Schmidt, MD;Samuel M. Rubinstein, MD

BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

A brief review of non–BCMA-targeted bispecific antibodies under investigation in patients with relapsed/refractory multiple myeloma.

Sagar Lonial, MD, FACP;Sandy Wong, MD;Caitlin Costello, MD;Timothy Schmidt, MD;Samuel M. Rubinstein, MD

Treatment Strategies for Patients With Transplant-Ineligible NDMM

Expert perspectives on recent clinical data on BCMA-targeted bispecific antibody therapy in patients with relapsed/refractory multiple myeloma.

Beth Faiman, PhD, MSN, APN-BC;Sandra Mazzoni, MD;Jack Khouri, MD;Louis Williams, MD

February 10th 2023

Expert perspectives on selection of induction therapy for patients with transplant-ineligible newly diagnosed multiple myeloma.

Patient Case 2: Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Beth Faiman, PhD, MSN, APN-BC;Sandra Mazzoni, MD;Jack Khouri, MD;Louis Williams, MD

February 10th 2023

Panelists move on to review a patient case of transplant-ineligible newly diagnosed multiple myeloma and highlight clinical workup strategies.

Relapsed/Refractory Multiple Myeloma: Overview of Treatment Options

Melissa Alsina, MD;Rachid Baz, MD;Brandon Blue, MD;Ken Shain, MD, PhD

Patient Profile 2: Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Switching their focus to the relapsed/refractory setting, experts from the Moffit Cancer Center consider second-line treatment options for patients with multiple myeloma.

Melissa Alsina, MD;Rachid Baz, MD;Brandon Blue, MD;Ken Shain, MD, PhD

The Role of Teclistamab in Multiple Myeloma

Expert perspectives on a patient profile of transplant-ineligible multiple myeloma, with considerations for treatment selection and defining transplant ineligibility.

Patient Experience With Treatment for Multiple Myeloma and Clinical Trial Participation

Dr Ajai Chari explains the mechanism of action of BCMA-targeting bispecifics and the role of teclistamab in multiple myeloma treatment.

Induction Therapy in Transplant-Ineligible NDMM

Anne-Marie Jacob describes her early treatment regimen for multiple myeloma and her experience with clinical trial enrollment.

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD

Role of Transplant and Induction Therapies in NDMM

A panel of expert oncologists consider treatment options for patients with NDMM that are transplant-ineligible.

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD

Selecting Treatment Regimens for Multiple Myeloma at First Relapse

Expert perspectives on the role of transplants and induction therapy in patients with newly diagnosed multiple myeloma (NDMM).

Sagar Lonial, MD, FACP;Sandy Wong, MD;Caitlin Costello, MD;Timothy Schmidt, MD;Samuel M. Rubinstein, MD

Choosing the Right Treatment for Patients With Transplant Ineligible MM

Turning to the last module, expert panelists discuss the treatment armamentarium for patients experiencing early relapse in multiple myeloma.

Sagar Lonial, MD, FACP;Sandy Wong, MD;Caitlin Costello, MD;Timothy Schmidt, MD;Samuel M. Rubinstein, MD